Geetanjali Tolia Chilkoti

Dr. Geetanjali Tolia Chilkoti

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Anaesthesiology Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
GCGeetanjali Tolia Chilkoti
Geetanjali Tolia Chilkoti
ASAnshul Singh
Anshul Singh
MMMedha Mohta
Medha Mohta
ASAshok Kumar Saxena
Ashok Kumar Saxena
Various exogenous steroid preparations have been in use for a wide range of indications. We, as an anesthesiologist often encounters a surgical patient receiving chronic steroid therapy. Perioperative use of steroid is associated with major complications such as full-blown adrenal crisis in the perioperative period due to the secondary adrenal insufficiency. Henceforth, comes the role of the perioperative “stress-dose” of steroids to mitigate this rare but potentially fatal complication. There have been opposing views regarding the need and the appropriate dosage of the perioperative steroids. The present review discusses the changing concept of perioperative “stress dose” of corticosteroids, its pharmacokinetics, clinical relevance, and the related controversies such as the need and the appropriate dose.

7 June 2021 in Pain Medicine
Verified
Journal Article
Open access
PDF file
ASAshok Kumar Saxena
Ashok Kumar Saxena
NBNeha Bhardwaj
Neha Bhardwaj
GCGeetanjali Tolia Chilkoti
Geetanjali Tolia Chilkoti
AMAnish Malik
Anish Malik
GTGaurav Kumar Thakur
Gaurav Kumar Thakur
ASArchana Singal
Archana Singal
This study was designed to explore the efficacy and feasibility of cognitive behavioral therapy (CBT) along with pregabalin and compare it with pregabalin monotherapy for the management of neuropathic pain in post-herpetic neuralgia (PHN) patients and to explore the modulation of messenger RNA (mRNA) expression of interleukin (IL)-6 and mammalian target of rapamycin-1 (mTORC1) genes in these patients. Randomized controlled pilot study. The patients aged >18 years of age with an established diagnosis of PHN with evident allodynia and hyperalgesia who had pain for at least 3 months after healing of rash with pain intensity ≥4/10 on NRS-Pain Scale were enrolled. The trial was registered with the Clinical Trials Registry-India (CTRI/2019/03/018014). A detailed baseline assessment regarding type and duration of pain and disability using pain-relevant self-report questionnaires was done. Two mL venous blood samples were collected for gene expression studies at base line and at end of 12 weeks of treatment. Patients were randomized into one of the two groups. Group PR received pregabalin and Group CP received CBT along with pregabalin. The pain intensity was measured using numeric rating scale (NRS)-Pain scale, neuropathic component of the pain by using Neuropathic Pain Symptom Inventory (NPSI) and Pain Detect Questionnaire (PDQ), sleep interference by NRS-Sleep, pain-related catastrophic thoughts by using Pain Catastrophizing Scale (PCS), depression and quality of life using Beck Depression Inventory-II (BDI-II) and Short Form-12 (SF-12), respectively. The research funding was supported by the intramural grant from the institution. A total of 40 patients with 20 in each group were included. Following integrated approach encompassing CBT and Pregabalin, group CP had significant downregulation of mRNA expression of IL-6; however, no such correlation was observed with mTOR expression. A significant decline in the intensity of pain, NPSI scoring for burning, allodynia, and pain-related catastrophizing were observed; also a significant improvement in depressive symptoms and quality of life were observed with the use of CBT. A significant downregulation of mRNA expression of IL-6 was observed; however, no significant correlation was observed between NRS pain score and ΔCt values of mRNA expression of both mTORC1 gene and IL-6 gene at baseline and at the end of 12th week. In addition, we note a significant decrease in pain intensity, depressive symptoms, and pain-related catastrophizing while improving QOL was observed with the use of CBT as a clinical adjunct along with pregabalin in PHN patients.

31 October 2016 in The Korean Journal of Pain
Verified
Journal Article
Open access
PDF file
ASAshok Kumar Saxena
Ashok Kumar Saxena
GCGeetanjali Tolia Chilkoti
Geetanjali Tolia Chilkoti
ACAnand K Chopra
Anand K Chopra
BBBasu Dev Banerjee
Basu Dev Banerjee
TSTusha Sharma
Tusha Sharma
Saxena AK, et al. Korean J Pain. 2016 Oct;29(4):239-248. https://doi.org/10.3344/kjp.2016.29.4.239

1 February 2019 in Indian Journal of Anaesthesia
Verified
Journal Article
Open access
GCGeetanjali Tolia Chilkoti
Geetanjali Tolia Chilkoti
MKManish Kumar
Manish Kumar
MMMedha Mohta
Medha Mohta
ASAshok Kumar Saxena
Ashok Kumar Saxena
NSNaveen Sharma
Naveen Sharma
JSJitender Singh
Jitender Singh
Background and Aims: Recently, low-dose intravenous (IV) dexmedetomidine has been evaluated for obtunding the pneumoperitoneum-induced haemodynamic changes and its analgesic efficacy in laparoscopic cholecystectomy. The aim was to determine the postoperative analgesic efficacy of low-dose bolus of 0.5 μg/kg dexmedetomidine via IV and intraperitoneal (IP) route in laparoscopic cholecystectomy. Methods: Seventy-five patients, aged 18–60 years of ASA physical status I and II, undergoing laparoscopic cholecystectomy under general anaesthesia were included. Patients in Group C received IP bupivacaine. Patients in Group IV received 0.5 μg/kg dexmedetomidine infusion IV after removal of gall bladder along with IP bupivacaine and Group IP received 0.5 μg/kg dexmedetomidine in 40 mL of 0.25% bupivacaine IP. The primary outcome was 'time to first request of analgesia' and the secondary outcomes were 'total consumption of tramadol in 24 hours,' visual analogue scale (VAS) pain score. Results: In total, 75 patients with 25 in each group were included. Time to first request of analgesia was found to be significantly lower in IV (59.68 ± 71.05 min, P = 0.00) and IP group (90.80 ± 80.46 min, P = 0.001) compared tp Group C (59.68 ± 71.05 min). Mean tramadol consumption in 24 hours (152.40 ± 60.958 vs 137.64 ± 52.40 mg) and mean VAS pain score were comparable in both IV and IP groups in the initial 12 h. Conclusion: Low bolus dose of IP dexmedetomidine is as efficacious as IV dexmedetomidine (0.5 μg/kg) along with IP bupivacaine in laparoscopic cholecystectomy.

1 January 2019 in Anesthesia: Essays and Researches
Verified
Journal Article
Open access
GCGeetanjali Tolia Chilkoti
Geetanjali Tolia Chilkoti
ASAshokKumar Saxena
AshokKumar Saxena
ASAnshul Singh
Anshul Singh
GYGaurav Yadav
Gaurav Yadav
J Indian Prosthodont Soc, Official publication of Indian Prosthodontic Society

22 July 2022 in Indian Journal of Anaesthesia
Verified
Journal Article
Open access
GCGeetanjali Tolia Chilkoti
Geetanjali Tolia Chilkoti
DGDiksha Gaur
Diksha Gaur
ASAshok K Saxena
Ashok K Saxena
AGAnju Gupta
Anju Gupta
RARachna Agarwal
Rachna Agarwal
SJSapna Jain
Sapna Jain
Background and Aims: Ultrasound-guided transversalis fascia plane block (USG-guided TFPB) has recently been evaluated for post-caesarean acute pain management. We compared it with standard wound infiltration for both acute and chronic post-caesarean pain management. Methods: All patients undergoing caesarean section (CS) under subarachnoid block were included and randomised. Patients in group C received standard wound infiltration (20 ml of 0.375% ropivacaine) and group-T received bilateral USG-guided TFPB (20 ml of 0.375% ropivacaine) at the end of the surgery. Acute pain assessed using numeric rating scale (NRS), time to first request of analgesia and total rescue analgesic consumption in 24 hours. The incidence of chronic persistent post-surgical pain (CPSP), neuropathic pain component and quality of life (QoL) were assessed. Fisher’s exact test, Chi-square test, unpaired Student’s t-test and Mann-Whitney U test were used. Results: Sixty patients were included with 30 in each group. NRS score on rest at 6 th and 24 th hour and on active movement at 1 st hour was significantly decreased in group T. The “time to first request of analgesia” was statistically higher in group T, that is, 10.77 ± 1.39 h versus 6.30 ± 1.60 h. Five (16.6%) and two (6.6%) patients in groups C and T, respectively, required rescue analgesia in first 24 hours. 30% (n = 6) and 10% (n = 2) patients in groups C and T, respectively, developed CPSP. The neuropathic pain component was significantly reduced and QoL was significantly improved in group T. Conclusion: TFPB is efficacious for management of both acute and chronic post-caesarean pain management.